0.9167
전일 마감가:
$1.03
열려 있는:
$1.01
하루 거래량:
133.92K
Relative Volume:
1.17
시가총액:
$12.42M
수익:
$52.16M
순이익/손실:
$-48.60M
주가수익비율:
-0.2122
EPS:
-4.32
순현금흐름:
$-77.48M
1주 성능:
-24.86%
1개월 성능:
-40.08%
6개월 성능:
-77.42%
1년 성능:
-87.94%
Hookipa Pharma Inc Stock (HOOK) Company Profile
명칭
Hookipa Pharma Inc
전화
0114318906360
주소
350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK, NY
HOOK을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
HOOK
Hookipa Pharma Inc
|
0.9167 | 12.42M | 52.16M | -48.60M | -77.48M | -4.32 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Hookipa Pharma Inc Stock (HOOK) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-12-20 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
2024-11-15 | 재확인 | RBC Capital Mkts | Outperform |
2022-12-02 | 다운그레이드 | BofA Securities | Buy → Underperform |
2021-11-12 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2021-04-08 | 개시 | Morgan Stanley | Overweight |
2020-11-03 | 개시 | Truist | Buy |
2020-10-26 | 개시 | JMP Securities | Mkt Outperform |
2020-10-19 | 재개 | H.C. Wainwright | Buy |
2019-09-27 | 개시 | H.C. Wainwright | Buy |
2019-05-13 | 개시 | BofA/Merrill | Buy |
2019-05-13 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Hookipa Pharma Inc 주식(HOOK)의 최신 뉴스
Hookipa Pharma stock plunges to 52-week low of $1.11 amid steep decline By Investing.com - Investing.com South Africa
Hookipa Pharma stock plunges to 52-week low of $1.11 amid steep decline - Investing.com India
Hookipa Pharma (HOOK) Expected to Announce Quarterly Earnings on Friday - Defense World
HOOKIPA Pharma to participate in upcoming investor conferences in September - MarketScreener
Hookipa Pharma (HOOK) Expected to Announce Earnings on Thursday - Defense World
Hookipa Pharma stock hits 52-week low at $1.34 amid sharp decline - Investing.com Australia
Hookipa Pharma stock hits 52-week low at $1.34 amid sharp decline By Investing.com - Investing.com South Africa
HOOKIPA Pharma Inc. SEC 10-K Report - TradingView
Hookipa Pharma stock hits 52-week low at $1.56 amid downturn - Investing.com India
Hookipa Pharma stock hits 52-week low at $1.56 amid downturn By Investing.com - Investing.com South Africa
Will HOOKIPA Pharma Inc. (HOOK) Report Negative Q2 Earnings? What You Should Know - MSN
BRIEF—Proposed combination of Poolbeg with HOOKIPA called off - The Pharma Letter
HOOKIPA Pharma ends talks to acquire Poolbeg Pharma By Investing.com - Investing.com Australia
Poolbeg slumps as Hookipa merger is called off - pharmaphorum
Hookipa Pharma (NASDAQ:HOOK) Shares Down 4.8% – Time to Sell? - Defense World
Poolbeg Pharma PLC (AIM:POLB) Termination of proposed combination with HOOKIPA - Share Talk
Poolbeg merger off after HOOKIPA ends discussions - Proactive Investors
Poolbeg Pharma Says Hookipa Terminated Discussions On Proposed Merger - TradingView
HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”) - GlobeNewswire
HOOKIPA Pharma ends talks to acquire Poolbeg Pharma - Investing.com India
Failed Merger: Why HOOKIPA Pharma Walked Away from Poolbeg Deal - StockTitan
Hookipa Pharma stock hits 52-week low at $1.71 amid downturn - MSN
Hookipa Pharma announces enrollment completion of Phase 1b HB-500 trial - Yahoo Finance
Hookipa Pharma Files Petition to Validate Stockholder Actions at Annual Meetings - Defense World
HOOKIPA completes enrollment for HIV vaccine trial By Investing.com - Investing.com Nigeria
HOOKIPA Pharma seeks court validation for stockholder actions By Investing.com - Investing.com Australia
HOOKIPA completes enrollment for HIV vaccine trial - Investing.com India
HOOKIPA Pharma Announces Enrollment Completion of Phase 1b - GlobeNewswire
Game-Changing HIV Vaccine Trial Fully Enrolled: HOOKIPA's Path to Potential Cure - StockTitan
HOOKIPA Pharma Announces Enrollment Completion of Phase 1b Clinical Trial Evaluating HB-500 for the Treatment… - Informazione.it
Poolbeg Agrees to Bid Deadline Extension for Possible Hookipa Pharma Deal - MarketWatch
Poolbeg Pharma granted extension to PUSU Deadline - DirectorsTalk Interviews
Poolbeg and HOOKIPA given more time to agree merger deal - Proactive Investors USA
Poolbeg Pharma PLC (AIM:POLB) Offer Update – Extension to PUSU Deadline - Share Talk
Poolbeg Pharma and HOOKIPA Extend Merger Deadline Amid Positive Discussions - TipRanks
HOOKIPA Pharma seeks court validation for stockholder actions - MSN
Hookipa Pharma Seeks Validation for Stockholder Meetings - TipRanks
HOOK (HOOKIPA Pharma) Shares Outstanding (EOP) : 12.05 Mil (As of Sep. 2024) - GuruFocus.com
Hookipa Pharma stock hits 52-week low at $1.73 amid market challenges - Investing.com Nigeria
Hookipa Pharma Inc (HOOK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):